■色素沉着过度导致肤色不均匀,深色皮肤类型受到不成比例的影响。
■评估一种新型药物的疗效和安全性,不含氢醌(HQ),多峰色素校正血清(高级增亮治疗[ABT])与4%HQ在中度至重度色素沉着,包括黄褐斑.
■在这项分面研究中,ABT和4%HQ被局部应用于随机分配的面部两侧,每天两次,持续12周。色素沉着过度,肤色均匀度,改良黄褐斑面积和严重程度指数(mMASI),黄褐斑生活质量问卷(MelasQoL),自我评估问卷,和耐受性进行了评估。
■受试者(n=113;黄褐斑亚组,n=44)是亚洲人(22%),黑人/非洲裔美国人(27%)西班牙裔(22%),白人/高加索人(28%)。ABT取得了与4%总部相当的结果。ABT耐受性良好,在所有访视中,平均总体色素沉着较基线有所改善(第12周为-11.7%;P≤0.001),肤色均匀度(-8.8%,P≤.005),and,在黄褐斑亚组中,mMASI(-50.6%;P≤.011)和MelasQoL评分(第12周与基线相比,33.0对46.6,分别为;P≤.011),不同种族分组的结果相似。ABT优先于4%的总部,满意率高(≥89%)。
■没有单独评估每种治疗的生活质量改善。
■ABT的功效和安全性与面部色素沉着过度患者的4%HQ相当,包括黄褐斑,跨越多个种族/民族背景。
UNASSIGNED: Hyperpigmentation results in uneven skin tone, with darker skin types disproportionately affected.
UNASSIGNED: Assess efficacy and safety of a novel, hydroquinone (HQ)-free, multimodal pigment-correcting serum (Advanced Brightening Treatment [ABT]) versus 4% HQ in moderate to severe hyperpigmentation, including melasma.
UNASSIGNED: In this split-face study, ABT and 4% HQ were applied topically on randomly assigned facial sides twice daily for 12 weeks. Hyperpigmentation, skin tone evenness, modified Melasma Area and Severity Index (mMASI), Melasma Quality of Life Questionnaire (MelasQoL), self-assessment questionnaires, and tolerability were assessed.
UNASSIGNED: Subjects (n = 113; melasma subgroup, n = 44) were Asian (22%), Black/African American (27%), Hispanic (22%), and White/Caucasian (28%). ABT achieved comparable results to 4% HQ. ABT was well tolerated and resulted in improvement versus baseline at all visits in mean overall hyperpigmentation (-11.7% at week 12; P ≤ .001), skin tone evenness (-8.8%, P ≤ .005), and, in the melasma subgroup, mMASI (-50.6%; P ≤ .011) and MelasQoL scores (33.0 vs 46.6 for week 12 vs baseline, respectively; P ≤ .011), with similar results across racial subgroups. ABT was preferred over 4% HQ, with high satisfaction rate (≥89%).
UNASSIGNED: Quality of life improvements per treatment were not evaluated separately.
UNASSIGNED: Efficacy and safety of ABT is comparable to 4% HQ in individuals with facial hyperpigmentation, including melasma, across multiple racial/ethnic backgrounds.